CN1239163C - Medicine composition for treating cerebrovascular disease - Google Patents
Medicine composition for treating cerebrovascular disease Download PDFInfo
- Publication number
- CN1239163C CN1239163C CN 03121958 CN03121958A CN1239163C CN 1239163 C CN1239163 C CN 1239163C CN 03121958 CN03121958 CN 03121958 CN 03121958 A CN03121958 A CN 03121958A CN 1239163 C CN1239163 C CN 1239163C
- Authority
- CN
- China
- Prior art keywords
- total
- filter
- ethanol
- radix
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medical composition for treating cerebrovascular disease, particularly to for ischemic cerebral apoplexy and secondary lesion caused by the ischemic cerebral apoplexy, which comprises 30 to 60 wt% of Panax notoginsenosides, 30 to 60 wt% of kudzuvine root total flavonoid and 1 to 15 wt% of american ginseng total saponin, and the total weight of the Panax notoginsenosides, the kudzuvine root total flavonoid and the american ginseng total saponin is 100 wt%.
Description
Invention field
The present invention relates to a kind of prevention and treatment cerebrovascular disease, the pharmaceutical composition of ischemia apoplexy and the secondary injury that causes thus especially is referred to as golden gloomy brain Thailand again.
Background technology
Ischemia apoplexy is mainly in middle-aged and elderly people, is caused by cerebral thrombosis usually, and onset is more anxious, and sequela occurs easily, as hemiplegia.Because this disease morbidity suddenly, and the consequence that causes is serious, therefore, it is significant to seek the medicine that effectively prevents and/or treats ischemia apoplexy.
Summary of the invention
The purpose of this invention is to provide a kind of effective treatment cerebrovascular disease, especially ischemia apoplexy reaches the pharmaceutical composition of the secondary injury that causes thus.
Pharmaceutical composition of the present invention comprises:
Radix Notoginseng total arasaponins 30-60wt%,
Radix Puerariae total flavones 30-60wt% and
Total panaquilon 1-15wt%, three's gross weight is 100wt%.
Pharmaceutical composition of the present invention preferably includes:
Radix Notoginseng total arasaponins 40-50wt%,
Radix Puerariae total flavones 40-50wt% and
Total panaquilon 5-10wt%, three's gross weight is 100wt%.
Radix Notoginseng total arasaponins, Radix Puerariae total flavones and total panaquilon can obtain according to the conventional extracting method of this area, and extracting method is not special the restriction.Wherein in the Radix Notoginseng total arasaponins Radix Notoginseng total arasaponins content preferably more than 50%, preferred more than 70%, more preferably more than 90%, in the Radix Puerariae total flavones Radix Puerariae total flavones content preferably more than 50%, preferred more than 70%, more preferably more than 90%.Total panaquilon content is preferably more than 50% in the total panaquilon, and is preferred more than 70%, more preferably more than 90%.
Preferably, Radix Notoginseng total arasaponins is prepared by the following step:
Radix Notoginseng is used alcohol reflux, filter, from filtrate recycling ethanol, be evaporated to the fluid extract that relative density is 1.10-1.20 again, use water dissolution, filter, filtrate is separated with resin column, is washed to the sugar-free reaction, and reuse ethanol is resolved, the alcoholic solution concentrating under reduced pressure is removed solvent and is promptly got Radix Notoginseng total arasaponins.
Preferably, Radix Puerariae total flavones is prepared by the following step:
With the Radix Puerariae alcohol reflux, filter, from filtrate recycling ethanol, be evaporated to the fluid extract that density is 1.30-1.40 again, again with water dissolution, filter, filtrate is separated with resin column, washes with water to the sugar-free reaction, and reuse ethanol is resolved, the alcoholic solution concentrating under reduced pressure is removed solvent and is promptly got Radix Puerariae total flavones.
Preferably, total panaquilon is prepared by following steps:
The Radix Panacis Quinquefolii alcohol reflux filters, and reclaims ethanol, is evaporated to the fluid extract that relative density is 1.10-1.20 again, use water dissolution, filter, filtrate is separated with resin column, is washed to the sugar-free reaction, reuse ethanol is resolved, and the alcoholic solution concentrating under reduced pressure is removed solvent and promptly got total panaquilon.
Used ethanol for example can be 10-95% ethanol, consumption can for 3-10 doubly to the crude drug amount.Reflux, extract, can be carried out repeatedly, and for example 2-10 time, each half an hour to 2 hour.Each reflux extracting liquid is merged.
Above-mentioned three kinds of compositions are merged, obtain compositions of the present invention.
Pharmaceutical composition of the present invention can be made the dosage form that is suitable for clinical practice arbitrarily, for example injection, tablet, drop pill, capsule etc.
Amount of drug of the present invention decides according to factors such as the weight of the state of an illness, patient age, sex, body weight.As guidance, be generally consumption per day 20-60mg 10-20mg/ time.
Clinical indication:
Cerebral infarction, and the secondary injury that causes thus, i.e. cerebral thrombosis acute stage and convalescent period.Chinese medical discrimination belongs to the wind-phlegm blood stasis numbness resistance venation card and the syndrome of blood stasis due to qi deficiency of apoplexy meridians.
Come further to set forth the present invention by the following examples.Be noted that the embodiment that is provided only sets forth certain embodiments of the present invention as an example, they do not limit the scope of the invention.
Specific embodiment
It is coarse powder that Radix Notoginseng is pulverized, and adds 75% ethanol of 3 times of amounts, reflux 7 times, each 1 hour, filter merging filtrate, reclaim ethanol, being evaporated to relative density is the fluid extract of 1.10-1.20 (25 ℃), filters with 2 times of water dissolutioies to crude drug, filtrate is by after the macroporous resin column, wash with water earlier to the sugar-free reaction, reuse ethanol is resolved, the alcoholic solution concentrating under reduced pressure, remove solvent, promptly get Radix Notoginseng total arasaponins (content 50-100%).
It is coarse powder that Radix Puerariae is pulverized, and adds 80% ethanol of 7 times of amounts, reflux 3 times, each 1 hour, filter merging filtrate, reclaim ethanol, being evaporated to relative density is the fluid extract of 1.30-1.40 (50 ℃), with 2 times of water dissolutioies to crude drug, filter, filtrate is by after the macroporous resin column, washes with water earlier to sugar-free to react, reuse ethanol is resolved, the alcoholic solution concentrating under reduced pressure is removed solvent, promptly gets Radix Puerariae total flavones (content 50-100%).
Radix Panacis Quinquefolii is pulverized, added 75% ethanol of 3 times of amounts, reflux 5 times, each 3 hours, filter merging filtrate, reclaim ethanol, be evaporated to the fluid extract of relative density 1.10-1.20 (25 ℃), filter with 2 times of water dissolutioies to crude drug, filtrate is by behind the macroporous resin, wash with water earlier to the sugar-free reaction, reuse ethanol is resolved, the alcoholic solution concentrating under reduced pressure, remove solvent, promptly get Radix Panacis Quinquefolii general glycoside (content 50-100%).
Above three kinds of total composition Radix Notoginseng total arasaponins, Radix Puerariae flavone and total panaquilons are pressed 40wt%, 55wt% and 5wt% respectively; 50wt%, 40wt% and 10wt%; Even with the mixed of 60wt%, 30wt% and 10wt%, add an amount of proppant, obtain crude drug.
Crude drug is prepared injection with water for injection, packing then, and lyophilization promptly gets injectable powder.
Crude drug adds wetting agent, granulates, and drying is mixed with wetting agent, and tabletting promptly gets tablet.
The crude drug heating and melting, system is dripped, and cools off in liquid paraffin, takes out drop pill, washing, drying promptly gets drop pill.
Crude drug mixes with fluidizer, and is encapsulated, promptly gets capsule.
The effect of medicine of the present invention
Brain tissue impairment due to treatment rat part and the full brain alleviates the brain necrosis area, and the protection cerebral tissue alleviates the brain function infringement, reduces the generation of MDA, slows down energy metabolism, improves the hypoxia-bearing capability of cerebral tissue.
Reduce vascular resistance, increase the blood flow of dog brain and mice meninges.
Directly protection Mus cranial nerve cell improves its hypoxia-bearing capability.
Obviously reduce Mus cerebral ischemia reperfusion hindbrain inner cell membrane lipid peroxide MDA content.
Prolong the time-to-live under the mice normobaric hypoxia state, reduce the energy metabolism level of cerebral tissue, suppress the generation of MDA, the protection cerebral tissue.
Suppress ADD and the inductive platelet aggregation of AA, hematoblastic adhesiveness is had certain inhibitory action.The high blood coagulation state that the cerebral ischemia animal is occurred has significantly antagonism.Reduce whole blood viscosity, and antithrombotic forms.
Claims (4)
1, a kind of treatment cerebrovascular disease, especially ischemia apoplexy reaches the pharmaceutical composition of the secondary injury that causes thus, and described pharmaceutical composition comprises:
Radix Notoginseng total arasaponins 30-60wt%,
Radix Puerariae total flavones 30-60wt% and
Total panaquilon 1-15wt%, three's gross weight is 100wt%; Wherein Radix Notoginseng total arasaponins is prepared by the following step: Radix Notoginseng is used alcohol reflux, filter, from filtrate recycling ethanol, be evaporated to the fluid extract that relative density is 1.10-1.20 again, use water dissolution, filter, filtrate is separated with resin column, is washed to the sugar-free reaction, and reuse ethanol is resolved, the alcoholic solution concentrating under reduced pressure is removed solvent promptly; Wherein Radix Puerariae total flavones is prepared by the following step: with the Radix Puerariae alcohol reflux, filter, from filtrate recycling ethanol, be evaporated to the fluid extract that density is 1.30-1.40 again, again with water dissolution, filter, filtrate is separated with resin column, washes with water to the sugar-free reaction, and reuse ethanol is resolved, the alcoholic solution concentrating under reduced pressure is removed solvent promptly; Wherein total panaquilon is prepared by following steps:
With the Radix Panacis Quinquefolii alcohol reflux, filter, reclaim ethanol, be evaporated to the fluid extract that relative density is 1.10-1.20 again, use water dissolution, filter, filtrate is separated with resin column, is washed to the sugar-free reaction, reuse ethanol is resolved, and the alcoholic solution concentrating under reduced pressure is removed solvent promptly.
2, according to the pharmaceutical composition of claim 1, comprising:
Radix Notoginseng total arasaponins 40-50wt%,
Radix Puerariae total flavones 40-50wt% and
Total panaquilon 5-10wt%, three's gross weight is 100wt%.
3, the purposes of each pharmaceutical composition in preparation treatment cerebrovascular disease medicament among the claim 1-2.
4,, it is characterized in that the purposes in preparation treatment ischemia apoplexy medicine according to the purposes of claim 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03121958 CN1239163C (en) | 2003-04-18 | 2003-04-18 | Medicine composition for treating cerebrovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03121958 CN1239163C (en) | 2003-04-18 | 2003-04-18 | Medicine composition for treating cerebrovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1537540A CN1537540A (en) | 2004-10-20 |
| CN1239163C true CN1239163C (en) | 2006-02-01 |
Family
ID=34320915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03121958 Expired - Lifetime CN1239163C (en) | 2003-04-18 | 2003-04-18 | Medicine composition for treating cerebrovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1239163C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105233246A (en) * | 2015-11-11 | 2016-01-13 | 安徽生物肽产业研究院有限公司 | Woodlouse small peptide drug for treating ischemic stroke |
| CN105664131A (en) * | 2016-01-13 | 2016-06-15 | 安徽生物肽产业研究院有限公司 | Hirudo small peptide effective part composition used for treating cardiovascular disease |
-
2003
- 2003-04-18 CN CN 03121958 patent/CN1239163C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1537540A (en) | 2004-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1927293A (en) | Chinese medicine composition for treating skin burn and scald | |
| CN1239163C (en) | Medicine composition for treating cerebrovascular disease | |
| CN1250253C (en) | Chinese medicine capsule for treating ischemic cerebral apoplexy | |
| CN1771978A (en) | Notoginseng triol-saponin composition and its prepn and use | |
| CN100479837C (en) | Weinakang for treating ischemic cerebrovascular disease and senile dementia and preparation method thereof | |
| CN1692916A (en) | Pharmaceutical prepn. of compound mannite, and its prepn. method | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1238028C (en) | Method for preparing capsule of six drugs containing rehmannine | |
| CN1935183A (en) | Chinese medicine compound preparation and its preparing method | |
| CN1810269A (en) | Freeze dried perhexiline powder for injection and its prepn process | |
| CN1143684C (en) | Medicine for treating hypertension and heart disease and its preparation | |
| CN1283303C (en) | Medicine composition for ischemia apoplexy | |
| CN1544021A (en) | Chinese traditional medicine preparation Qishenmai for treating coronary heart disease and angina pectoris and its preparing process | |
| CN1698693A (en) | Chest relaxing drop pills and preparation method thereof | |
| CN1915245A (en) | Medicinal composition, preparation method and quality control method | |
| CN1915256A (en) | Medicinal composition, preparation method and quality control method | |
| CN101028330A (en) | Medicinal composition for treating cardiovascular disease, its production and use | |
| CN1957978A (en) | Composition of medication for treating cardiovascular disease, cerebrovascular disease, preparation method and application | |
| CN1634177A (en) | Puncturevine fruit and sichuan lovage rhizome containing dripping pills for treating cardiovascular and cerebrovascular disease and its preparation method | |
| CN1957976A (en) | Composition of medication for treating cardiovascular disease, cerebrovascular disease, preparation method and application | |
| CN1957974A (en) | Composition of medication for treating cardiovascular disease, cerebrovascular disease, preparation method and application | |
| CN1915254A (en) | Medicinal composition, preparation method and quality control method | |
| CN1957977A (en) | Composition of medication for treating cardiovascular disease, cerebrovascular disease, preparation method and application | |
| CN1954831A (en) | Medical composite for treating cardio-cerebral vascular disease and its preparation method and application | |
| CN1915265A (en) | Medicinal composition, preparation method and quality control method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HARBIN SANCTITY BIOPHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHENGTAI PHARMACEUTICAL CO., LTD., HARBIN Effective date: 20120428 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 150525 HARBIN, HEILONGJIANG PROVINCE TO: 150025 HARBIN, HEILONGJIANG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120428 Address after: 150025, Beijing Road, Limin Development Zone, Harbin, 99 Patentee after: HARBIN SANCTITY BIOLOGICAL PHARMACEUTICAL Co.,Ltd. Address before: 150525, 99 Beijing Road, Limin economic and Technological Development Zone, Heilongjiang, Harbin Patentee before: Shengtai Pharmaceutical Co.,Ltd. Harbin |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060201 |
|
| CX01 | Expiry of patent term |